Monopar Therapeutics Inc. - Common Stock (NQ:MNPR)

64.39 -0.68 (-1.05%)

Streaming Delayed Price Updated: 3:07 PM EST, Dec 31, 2025 Add to My Watchlist

Price and Volume

Volume	259,738
Open	64.49
Bid (Size)	63.74 (100)
Ask (Size)	64.80 (100)
Prev. Close	65.07
Today's Range	63.73 - 65.60
52wk Range	21.00 - 105.00
Shares Outstanding	14,157,941
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

Today 14:16 EST

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

November 14, 2025

Via Benzinga

Performance

YTD	+189.8%	+189.8%
1 Month	-22.5%	-22.5%
3 Month	-21.2%	-21.2%
6 Month	+91.9%	+91.9%
1 Year	+170.0%	+170.0%

More News

Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments

November 13, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

November 09, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025

October 15, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

October 13, 2025

Via Benzinga

CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗

September 25, 2025

Via Benzinga

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

September 23, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

September 23, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout ↗

September 15, 2025

Via Investor's Business Daily

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

September 14, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

September 03, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

August 12, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

June 23, 2025

Via Benzinga

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

June 11, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

June 03, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

May 13, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

May 07, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

April 29, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

March 31, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 21, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 20, 2024

Via Benzinga

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

December 20, 2024

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

December 05, 2024

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

December 03, 2024

From Monopar Therapeutics Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Monopar Therapeutics Inc. - Common Stock publicly traded?

Yes, Monopar Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Monopar Therapeutics Inc. - Common Stock trade on?

Monopar Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Monopar Therapeutics Inc. - Common Stock?

The ticker symbol for Monopar Therapeutics Inc. - Common Stock is MNPR on the Nasdaq Stock Market

What is the current price of Monopar Therapeutics Inc. - Common Stock?

The current price of Monopar Therapeutics Inc. - Common Stock is 64.39

When was Monopar Therapeutics Inc. - Common Stock last traded?

The last trade of Monopar Therapeutics Inc. - Common Stock was at 12/31/25 03:07 PM ET

What is the market capitalization of Monopar Therapeutics Inc. - Common Stock?

The market capitalization of Monopar Therapeutics Inc. - Common Stock is 911.57M

How many shares of Monopar Therapeutics Inc. - Common Stock are outstanding?

Monopar Therapeutics Inc. - Common Stock has 912M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.